Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease

Journal of Physiology and Biochemistry

Volumn 67, Issue 3, 2011, Pages 437-441

  Kotani, Kazuhiko ^a,b   Kimura, Satoshi ^c   Gugliucci, Alejandro ^b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b TOURO UNIVERSITY CALIFORNIA   (United States)

^c SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

Author keywords

Atherosclerosis; Cardiovascular disease; Oxidation; Renal failure

Indexed keywords

ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKER; ISCHEMIA MODIFIED ALBUMIN; ISCHEMIA-MODIFIED ALBUMIN; PON1 PROTEIN, HUMAN; SERUM ALBUMIN;

BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; HUMAN; RENAL REPLACEMENT THERAPY; REVIEW;

ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; SERUM ALBUMIN;

EID: 84856388037     PISSN: 11387548     EISSN: 18778755     Source Type: Journal    
DOI: 10.1007/s13105-011-0092-4     Document Type: Short Survey

References (41)

1. Aviram M, Rosenblat M (2005) Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol 16:393-399 (Pubitemid 41017622)
2. Bar-Or D, Curtis G, Rao N, Bampos N, Lau E (2001) Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem 268:42-47 (Pubitemid 32054374)
3. Bhagavan NV, Lai EM, Rios PA, Yang J et al (2003) Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem 49:581-585 (Pubitemid 36379523)
4. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R et al (2008) Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299:1265-1276 (Pubitemid 351439073)
5. Cheung AK (2009) Is lipid control necessary in hemodialysis patients? Clin J Am Soc Nephrol 4(Suppl 1):S95-S101
6. Dantoine TF, Debord J, Charmes JP, Merle L et al (1998) Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 9:2082-2088 (Pubitemid 28482156)
7. Dirican M, Akca R, Sarandol E, Dilek K (2004) Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol 17:813-818 (Pubitemid 41158301)
8. Duarte MM, Rocha JB, Moresco RN, Duarte T et al (2009) Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clin Biochem 42:666-671
9. Efstratiadis G, Tziomalos K, Mikhailidis DP, Athyros VG, Hatzitolios A (2008) Atherogenesis in renal patients: a model of vascular disease? Curr Vasc Pharmacol 6:93-107
10. Ferretti G, Bacchetti T, Masciangelo S, Pallotta G (2008) Lipid peroxidation in hemodialysis patients: effect of vitamin C supplementation. Clin Biochem 41:381-386
11. Ferretti G, Bacchetti T, Moroni C, Savino S et al (2005) Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab 90:1728-1733 (Pubitemid 40464045)
12. Gugliucci A, Lunceford N, Kinugasa E, Ogata H, Schulze J, Kimura S (2007) Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients. Clin Chim Acta 384:105-112 (Pubitemid 47260577)
13. Gugliucci A, Mehlhaff K, Kinugasa E, Ogata H et al (2007) Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance. Clin Chim Acta 377:213-220 (Pubitemid 44920216)
14. Hasselwander O, McMaster D, Fogarty DG, Maxwell AP, Nicholls DP, Young IS (1998) Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure. Clin Chem 44:179-181 (Pubitemid 28042485)
15. Ikeda Y, Suehiro T, Itahara T, Inui Y et al (2007) Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. Clin Nephrol 67:358-365 (Pubitemid 46894800)
16. Itahara T, Suehiro T, Ikeda Y, Inoue M et al (2000) Serum paraoxonase and arylesterase activities in hemodialysis patients. J Atheroscler Thromb 7:152-158
17. Jurek A, Turyna B, Kubit P, Klein A (2006) LDL susceptibility to oxidation and HDL antioxidant capacity in patients with renal failure. Clin Biochem 39:19-27 (Pubitemid 43005266)
18. Juretić D, Tadijanović M, Rekić B, Simeon-Rudolf V et al (2001) Serum paraoxonase activities in hemodialyzed uremic patients: cohort study. Croat Med J 42:146-150 (Pubitemid 32525313)
19. Kao MP, Ang DS, Pall A, Struthers AD (2010) Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options. J Hum Hypertens 24:1-8
20. Kotani K, Kimura S, Kinugasa E, Ogata H, et al. (2010) Relationship between the serum levels of paraoxonase-1 and ischemia-modified albumin in subjects with end-stage renal disease on hemodialysis: a pilot study. J Comp Clin Med (in press)
21. La Du BN, Adkins S, Kuo CL, Lipsig D (1993) Studies on human serum paraoxonase/arylesterase. Chem Biol Interact 87:25-34 (Pubitemid 23205359)
22. Mackness MI, Durrington PN, Mackness B (2004) The role of paraoxonase 1 activity in cardiovascular disease: potencial for therapeutic intervention. Am J Cardiovasc Drugs 4:211-217 (Pubitemid 39206616)
23. Montagnana M, Lippi G, Tessitore N, Salvagno GL et al (2008) Effect of hemodialysis on traditional and innovative cardiac markers. J Clin Lab Anal 22:59-65 (Pubitemid 351272482)
24. Moradi H, Pahl MV, Elahimehr R, Vaziri ND (2009) Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res 153:77-85
25. Pantazopoulos I, Papadimitriou L, Dontas I, Demestiha T, Iakovidou N, Xanthos T (2009) Ischaemia modified albumin in the diagnosis of acute coronary syndromes. Resuscitation 80:306-310
26. Paragh G, Asztalos L, Seres I, Balogh Z et al (1999) Serum paraoxonase activity changes in uremic and kidney-transplanted patients. Nephron 83:126-131 (Pubitemid 29447506)
27. Paragh G, Seres I, Balogh Z, Varga Z et al (1998) The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 80:166-170 (Pubitemid 28458792)
28. Piwowar A, Knapik-Kordecka M, Warwas M (2008) Ischemia-modified albumin level in type 2 diabetes mellitus - preliminary report. Dis Markers 24:311-317
29. Quaschning T, Krane V, Metzger T, Wanner C (2001) Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease. Am J Kidney Dis 38(4 Suppl 1):S14-S19 (Pubitemid 32927605)
30. Ritz E, Bommer J (2009) Cardiovascular problems on hemodialysis: current deficits and potential improvement. Clin J Am Soc Nephrol 4(Suppl 1):S71-S78
31. Saeed SA, Elsharkawy M, Elsaeed K, Fooda O (2008) Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients. Hemodial Int 12:471-479
32. Schiavon R, De Fanti E, Giavarina D, Biasioli S, Cavalcanti G, Guidi G (1996) Serum paraoxonase activity is decreased in uremic patients. Clin Chim Acta 247:71-80 (Pubitemid 26101430)
33. Sharma R, Gaze DC, Pellerin D, Mehta RL et al (2006) Ischemia-modified albumin predicts mortality in ESRD. Am J Kidney Dis 47:493-502 (Pubitemid 43255184)
34. Sharma R, Singh B, Mahajan M (2007) PON1 activity is inversely related to LDL apoB carbonyl content in patients with coronary artery disease. Kaohsiung J Med Sci 23:225-231 (Pubitemid 46953466)
35. Suehiro T, Ikeda Y, Shiinoki T, Inoue M et al (2002) Serum paraoxonase (PON1) concentration in patients undergoing hemodialysis. J Atheroscler Thromb 9:133-138
36. Tavori H, Vaya J, Aviram M (2010) Paraoxonase 1 attenuates human plaque atherogenicity: relevance to the enzyme lactonase activity. Adv Exp Med Biol 660:99-111
37. Turedi S, Cinar O, Yavuz I, Mentese A et al (2010) Differences in ischemia-modified albumin levels between end stage renal disease patients and the normal population. J Nephrol 23:335-340
38. Valle Gottlieb MG, da Cruz IB, Duarte MM, Moresco RN et al (2010) Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers. J Clin Endocrinol Metab 95:586-591
39. Vassalotti JA, Li S, Chen SC, Collins AJ (2009) Screening populations at increased risk of CKD: the Kidney Early Evaluation Program (KEEP) and the public health problem. Am J Kidney Dis 53(3 Suppl 3):S107-S114
40. Vaziri ND (2009) Causes of dysregulation of lipid metabolism in chronic renal failure. Semin Dial 22:644-651
41. Ward RA, McLeish KR (2003) Oxidant stress in hemodialysis patients: what are the determining factors? Artif Organs 27:230-236 (Pubitemid 36423478)